Trefoil Factor Family (TFF) Peptides and Their Links to Inflammation: A Re-evaluation and New Medical Perspectives

Trefoil factor family peptides (TFF1, TFF2, TFF3), together with mucins, are typical exocrine products of mucous epithelia. Here, they act as a gastric tumor suppressor (TFF1) or they play different roles in mucosal innate immune defense (TFF2, TFF3). Minute amounts are also secreted as endocrine, e.g., by the immune and central nervous systems. As a hallmark, TFF peptides have different lectin activities, best characterized for TFF2, but also TFF1. Pathologically, ectopic expression occurs during inflammation and in various tumors. In this review, the role of TFF peptides during inflammation is discussed on two levels. On the one hand, the expression of TFF1-3 is regulated by inflammatory signals in different ways (upstream links). On the other hand, TFF peptides influence inflammatory processes (downstream links). The latter are recognized best in various Tff-deficient mice, which have completely different phenotypes. In particular, TFF2 is secreted by myeloid cells (e.g., macrophages) and lymphocytes (e.g., memory T cells), where it modulates immune reactions triggering inflammation. As a new concept, in addition to lectin-triggered activation, a hypothetical lectin-triggered inhibition of glycosylated transmembrane receptors by TFF peptides is discussed. Thus, TFFs are promising players in the field of glycoimmunology, such as galectins and C-type lectins.


TFF Peptides: The "Classical" View
In humans, secretory trefoil factor family (TFF) peptides comprise TFF1, TFF2, and TFF3 (reviews: [1][2][3][4]). They share characteristic cysteine-rich modules (TFF domains [5]; formerly trefoil domains [6], P-domains [7]), where six cysteine residues form three intramolecular disulfide bridges in the order Cys I-V , Cys II-IV , and Cys III-VI (Figure 1). Both TFF1 and TFF3 contain a single TFF domain and a 7 th cysteine residue at their C-terminal outside the TFF domain (Cys VII ). In contrast, TFF2 contains two TFF domains and two additional cysteine residues, the latter connecting the C-and N-terminal via a disulfide bridge ( Figure 1). There are indications that the resulting circular structure occurs in different forms (maybe supercoils) [8,9]. In spite of their overall similarity, there is probably a major structural difference between TFF1 and TFF3 concerning the nucleophilicity of Cys VII , which is enhanced in TFF1 by steric exposure (neighboring proline residues, Figure 1). Remarkably, human TFF2 is N-glycosylated (gastric TFF2 bears an unusual fucosylated LacdiNAc oligosaccharide [10]); whereas murine and porcine TFF2 lack N-glycosylation sites. Generally, TFF peptides have been characterized from frogs to humans thus far [11]. Figure 1. Schematic structures of the three human TFF peptides. Cysteine residues (C; numbering in Roman numerals) and disulfide bridges are shown in green. TFF2 contains an additional disulfide bridge between Cys-6 and Cys-104 creating a circular structure; also represented are the proline residues (P) at the C-terminal outside the TFF domains. Acid residues in proximity to the Cterminal cysteine residues that modify its reactivity (change of pKa) are shown in red.
The major amounts of TFF peptides are secreted from mucous epithelia, where they are released together with mucins in an exocrine manner [4,[11][12][13]. TFF1 is mainly expressed in gastric surface mucous cells (together with the mucin MUC5AC), TFF2 istogether with MUC6-restricted to gastric mucous neck cells, antral gland cells and duodenal Brunner's glands, whereas TFF3 is a typical product of intestinal goblet cells and most other mucous epithelia and their glands. Consequently, TFFs are constituents of mucus barriers and appear also in the corresponding body fluids, such as saliva, gastric juice, and urine, as well as in tears and breast milk [3].
In the past, the biological/molecular function of TFF peptides was explained as a paradigm of their migratory effects, which were postulated to stimulate the rapid repair of mucous epithelia by a process called "restitution" [19]. Subsequently, many publications appeared reporting motogenic effects in vitro and protective or healing effects of TFFs in vivo (compilation: [11]). The three TFF peptides showed remarkably similar activities. Taken together, the effects observed were not really convincing as they were hardly detectable in vitro and occurred at concentrations of 10 −6 to 10 −7 M or even above [4,12,20]. This concentration is atypical of classical receptor/peptide ligand interactions and is in agreement with a failure to detect high-affinity TFF binding proteins [21]. Thus, rather low-affinity binding can be expected, which would be in agreement with the known, but different, lectin activities of TFF peptides [4,22]. Such a hypothetical function of TFF peptides as activating lectin ligands for a plethora of transmembrane glycoproteins triggering signal transduction processes has already been proposed in the past [23]. Currently, the following transmembrane proteins were reported to have a binding affinity for TFF peptides: β1 integrin [24], CRP-ductin/DMBT1 gp340 [24,25], CXCR4 and CXCR7 [26][27][28], PAR2 [29], PAR4 [30], LINGO2 [31], and LINGO3 [32]. Remarkably, many of these transmembrane proteins are known to support cell migration processes. Based on this rather diverse list, one might also expect that more members will be added in the near future (e.g., transmembrane mucins and other Cluster of Differentiation/CD molecules). However, it is the challenge now to clarify unambiguously whether signal transduction processes are triggered specifically by TFF peptides and to characterize the potential ligand binding in detail (e.g., dose-response curves for different forms of TFF1, TFF2, and TFF3), a major question being whether TFF peptide binding occurs via lectin or protein-protein interactions. Finally, the question arises on the biological significance of such processes in mucous epithelia (exocrine secretion) or mainly in organs with endocrine secretion of minute amounts of TFF peptides. Schematic structures of the three human TFF peptides. Cysteine residues (C; numbering in Roman numerals) and disulfide bridges are shown in green. TFF2 contains an additional disulfide bridge between Cys-6 and Cys-104 creating a circular structure; also represented are the proline residues (P) at the C-terminal outside the TFF domains. Acid residues in proximity to the C-terminal cysteine residues that modify its reactivity (change of pKa) are shown in red.
The major amounts of TFF peptides are secreted from mucous epithelia, where they are released together with mucins in an exocrine manner [4,[11][12][13]. TFF1 is mainly expressed in gastric surface mucous cells (together with the mucin MUC5AC), TFF2 is-together with MUC6-restricted to gastric mucous neck cells, antral gland cells and duodenal Brunner's glands, whereas TFF3 is a typical product of intestinal goblet cells and most other mucous epithelia and their glands. Consequently, TFFs are constituents of mucus barriers and appear also in the corresponding body fluids, such as saliva, gastric juice, and urine, as well as in tears and breast milk [3].
In the past, the biological/molecular function of TFF peptides was explained as a paradigm of their migratory effects, which were postulated to stimulate the rapid repair of mucous epithelia by a process called "restitution" [19]. Subsequently, many publications appeared reporting motogenic effects in vitro and protective or healing effects of TFFs in vivo (compilation: [11]). The three TFF peptides showed remarkably similar activities. Taken together, the effects observed were not really convincing as they were hardly detectable in vitro and occurred at concentrations of 10 −6 to 10 −7 M or even above [4,12,20]. This concentration is atypical of classical receptor/peptide ligand interactions and is in agreement with a failure to detect high-affinity TFF binding proteins [21]. Thus, rather low-affinity binding can be expected, which would be in agreement with the known, but different, lectin activities of TFF peptides [4,22]. Such a hypothetical function of TFF peptides as activating lectin ligands for a plethora of transmembrane glycoproteins triggering signal transduction processes has already been proposed in the past [23]. Currently, the following transmembrane proteins were reported to have a binding affinity for TFF peptides: β1 integrin [24], CRP-ductin/DMBT1 gp340 [24,25], CXCR4 and CXCR7 [26][27][28], PAR2 [29], PAR4 [30], LINGO2 [31], and LINGO3 [32]. Remarkably, many of these transmembrane proteins are known to support cell migration processes. Based on this rather diverse list, one might also expect that more members will be added in the near future (e.g., transmembrane mucins and other Cluster of Differentiation/CD molecules). However, it is the challenge now to clarify unambiguously whether signal transduction processes are triggered specifically by TFF peptides and to characterize the potential ligand binding in detail (e.g., dose-response curves for different forms of TFF1, TFF2, and TFF3), a major question being whether TFF peptide binding occurs via lectin or protein-protein interactions. Finally, the question arises on the biological significance of such processes in mucous epithelia (exocrine secretion) or mainly in organs with endocrine secretion of minute amounts of TFF peptides.
However, the concentrations of TFF peptides in mucous epithelia are rather high and it is unlikely that under physiological conditions they mainly act as activating high-affinity ligands of transmembrane receptors triggering intracellular signaling processes. This view is strengthened by long lasting systematic studies concerning the natural forms of TFF peptides in mucous epithelia [33][34][35][36][37]. As the major result, surprisingly, TFF peptides were found to appear in different molecular forms indicating diverse molecular functions. This led to a change in the paradigm concerning their molecular functions in healthy mucous epithelia [4].

Exocrine TFF Peptides Occur in Different Molecular Forms and Have Diverse Molecular Functions
Gastric TFF1 occurs mainly as a monomer with a highly exposed free thiol group at Cys VII as shown for humans [37], mice [9], and the Xenopus laevis ortholog xP1 [38]. Such an unpaired cysteine residue is unusual for secretory proteins, which normally undergo assembly, retention or degradation in the endoplasmic reticulum [39]. Similar to Ig light chains [40], TFF1 obviously escapes this fate probably due to the four acidic residues flanking Cys VII ( Figure 1). Furthermore, Cys VII is expected to be very nucleophilic because of its steric exposure by two proline residues in close proximity ( Figure 1). Thus, Cys VII would be ideally suited to serve as a scavenger for extracellular reactive oxygen/nitrogen species (ROS/RNS) [4,9,37,38]. In addition, TFF1 could also fulfill an intracellular function as a chaperone to ensure the correct folding and assembly of, for example, the gastric mucin MUC5AC [4,37,41]. Furthermore, minor amounts of TFF1 form disulfide-linked heterodimers with gastrokine 2 (GKN2) and IgG Fc binding protein (FCGBP) [9,33,37,42]. Finally, dimeric TFF1 has lectin activity toward both a core oligosaccharide of the Helicobacter pylori lipopolysaccharide as well as the carbohydrate moiety of the mucin MUC6 [37,43,44]. An αGlcNAc residue seems to be a common motif in these different structures, which is probably part of the recognition sequence of the lectin TFF1 [4].
In the intestine as well as saliva, TFF3 mainly occurs as a disulfide-linked hetero-dimer with FCGBP [34,51]. FCGBP is a repetitive, cysteine-rich glycoprotein (consisting of about 5400 amino acid residues) ubiquitously expressed in vertebrates and cephalochordates, where it is a characteristic secretory product of most mucin-producing cells (such as TFF3), and thus appears in the corresponding body fluids [47,52]. The molecular function of FCGBP has not been elucidated in detail. Generally, it is an early response gene after microbial infection and seems to play a role in the mucosal innate immune defense [20]; it likely regulates pathogen attachment and the clearing of microorganisms [53,54]. For example, FCGBP could bind IgG after its transcytosis via the neonanal Fc receptor (FcRn), and this complex could trap microbia, including viruses [55,56]. The hetero-dimerization of TFF3 and FCGBP could modulate the binding characteristics to microbia by a lectin activity of TFF3 [4,9,20]. A similar effect is expected for TFF1-FCGBP [9,37].

Pathological Expression of TFF Peptides: Links to Inflammation and Cancer
Soon after their discovery, ectopic expression of TFF peptides was detected in pathological conditions, particularly during chronic inflammation, such as gastro-esophageal reflux disease, Barrett esophagus, gastric and duodenal ulcers, diverticulitis, inflammatory bowel disease, pancreatitis, hepatholithiasis, cholecystitis, salpingitis, and inflammatory nasal polypi (for reviews, see [3,11,20,57]). These studies were mainly based upon histolog-ical results (immunofluorescence, immunohistochemistry, and in situ hybridization). In most of these cases, a glandular structure termed "ulcer-associated cell lineage" (UACL, also known as pyloric or pseudo-pyloric metaplasia) was described as the prominent site for TFF peptide synthesis [58]. For example, both TFF1 and TFF2 are ectopically expressed in Crohn's disease [59]. Furthermore, TFF2 and TFF3 were detected after mucosal injury/ulceration; TFF2 was expressed early, whereas TFF3 was a late response gene clearly indicating a different regulation of TFF2 and TFF3 [60]. Strongly increased levels of all three TFF peptides were also observed in the bronchioalveolar lavage fluid from patients with chronic obstructive lung disease (COPD) [61].
An acute inflammation is a defense mechanism of the immune system driven primarily by myeloid cells (e.g., macrophages). Macrophages are phagocytic cells of the innate immune system and they have remarkable plasticity. They have two states of polarized activation: classically activated (M1) and alternatively activated (M2) phenotypes. The latter is subdivided at least into three subtypes (M2a, M2b, and M2c) [69]. The activation and response of macrophages is controlled by subsets of differently polarized CD4 + T lymphocytes (Th1, Th2 and Th17 cells), each secreting signature cytokines and expressing a lineage-specifying transcription factor [70][71][72]. The type of immune response after injury or infection depends upon pathogen/danger-associated molecular patterns (PAMPs/DAMPs) and is characteristic for different pathogens (e.g., extracellular or intracellular bacteria, parasitic helminths, fungi, and viruses) [71]. These PAMPs and DAMPs, as well as ROS, are sensed by pattern-recognition receptors (PRRs), which are activators of the inflammasome and also direct triggers of (acute) inflammatory as well as regenerative processes (reparative inflammation) [73]. Furthermore, inflammation underlies many chronic and degenerative diseases. Of special note, most, but not all, chronic inflammatory diseases increase the risk of cancer [74,75]. An inflammatory environment is also a hallmark of cancer [76,77]. Thus, cytokines produced by activated immune cells are an important link between inflammation and cancer [78,79].
Numerous studies addressed the following question: which signals trigger the expression of TFF peptides during inflammation, and are there differences between the three TFF genes? Further questions asked were as follows: (i) is a loss of TFF peptides linked to inflammation, and (ii) is the expression of cytokines regulated by TFF peptides? The data concerning the multiple links of TFF peptides and inflammation are rather complex, partly seemingly controversial and often based upon single observations in a variety of very specialized systems. In order to get a glimpse on this complex interplay, the topic is discussed on two different levels ( Figure 2): (i) complex regulation of TFF expression by inflammatory mediators (upstream links; Section 2); and (ii) role of TFF peptides in inflammatory processes (downstream links; Section 3). This scheme does not exclude possible feedback loops, e.g., those between inflammatory processes and the regulation of TFF expression (see Section 4.1). expressed in Crohn's disease [59]. Furthermore, TFF2 and TFF3 were detected after mucosal injury/ulceration; TFF2 was expressed early, whereas TFF3 was a late response gene clearly indicating a different regulation of TFF2 and TFF3 [60]. Strongly increased levels of all three TFF peptides were also observed in the bronchioalveolar lavage fluid from patients with chronic obstructive lung disease (COPD) [61].
An acute inflammation is a defense mechanism of the immune system driven primarily by myeloid cells (e.g., macrophages). Macrophages are phagocytic cells of the innate immune system and they have remarkable plasticity. They have two states of polarized activation: classically activated (M1) and alternatively activated (M2) phenotypes. The latter is subdivided at least into three subtypes (M2a, M2b, and M2c) [69]. The activation and response of macrophages is controlled by subsets of differently polarized CD4 + T lymphocytes (Th1, Th2 and Th17 cells), each secreting signature cytokines and expressing a lineage-specifying transcription factor [70][71][72]. The type of immune response after injury or infection depends upon pathogen/danger-associated molecular patterns (PAMPs/DAMPs) and is characteristic for different pathogens (e.g., extracellular or intracellular bacteria, parasitic helminths, fungi, and viruses) [71]. These PAMPs and DAMPs, as well as ROS, are sensed by pattern-recognition receptors (PRRs), which are activators of the inflammasome and also direct triggers of (acute) inflammatory as well as regenerative processes (reparative inflammation) [73]. Furthermore, inflammation underlies many chronic and degenerative diseases. Of special note, most, but not all, chronic inflammatory diseases increase the risk of cancer [74,75]. An inflammatory environment is also a hallmark of cancer [76,77]. Thus, cytokines produced by activated immune cells are an important link between inflammation and cancer [78,79].
Numerous studies addressed the following question: which signals trigger the expression of TFF peptides during inflammation, and are there differences between the three TFF genes? Further questions asked were as follows: (i) is a loss of TFF peptides linked to inflammation, and (ii) is the expression of cytokines regulated by TFF peptides? The data concerning the multiple links of TFF peptides and inflammation are rather complex, partly seemingly controversial and often based upon single observations in a variety of very specialized systems. In order to get a glimpse on this complex interplay, the topic is discussed on two different levels ( Figure 2): (i) complex regulation of TFF expression by inflammatory mediators (upstream links; Section 2); and (ii) role of TFF peptides in inflammatory processes (downstream links; Section 3). This scheme does not exclude possible feedback loops, e.g., those between inflammatory processes and the regulation of TFF expression (see Section 4.1).

Figure 2.
Schematic representation of the multiple links between TFF peptides and inflammation. TFF expression is regulated by inflammatory mediators (upstream); TFF peptides (or their loss) also influence inflammatory processes (downstream). In contrast to previous reviews describing the situation in healthy mucous epithelia (including the function of TFF peptides in the mucosal innate immune defense [4,20]), here, the role of TFF peptides during pathological, inflammatory conditions is discussed.

Regulation of TFF Expression by Inflammatory Mediators
Multiple reports indicate a complex regulation of TFF gene expression. Typical regulatory signals include estrogen, pro-and anti-inflammatory cytokines, transforming growth factor α (TGFα), fibroblast growth factors (FGFs), gastrin, TFF peptides (interregulation), prostaglandins, arachidonic acid, indomethacin, aspirin, omeprazole, butyrate, hydrogen peroxide, osmotic stress, hypoxia, X-ray irradiation, and pathogens (reviews: [11,65,66,80,81]). The three human TFF genes share some cis acting elements in their promoter regions [82]. Here, based on molecular data, the regulation of TFF gene expression during inflammatory conditions will be discussed for selected cases.

Down-Regulation of TFF1 during Gastric Inflammation and Ectopic TFF1 Expression in Chronic Inflammatory Diseases
An infection of the stomach with H. pylori is accompanied by gastritis, leading to dysregulated expression of TFF peptides. In the human antrum, on the protein level, mainly TFF1 is reduced in infected individuals [83]. In a mouse model of H. pylori infection, TFF1 expression is initially somewhat up-regulated transcriptionally and then also downregulated about 14 days post-infection [84]. The down-regulation of TFF1 after H. pylori infection could be explained by a multi-step mechanism. First, H. pylori-infected cells (such as TFF1-secreting surface mucous cells) release interleukin (IL)-8 [85], which is a chemoattractant for neutrophils and macrophages. The latter then secrete IL-1β, which is the predominant pro-inflammatory cytokine produced in response to H. pylori infection; this shifts the immune response toward a Th1-axis (pro-inflammatory) [86]. From the in vitro data, one might conclude that IL-1β is responsible for the down-regulation of TFF1, as TFF1-3 expression is repressed by IL-1β (and IL-6) via nuclear factor κB (NF-κB) and CCAT/enhancer binding protein (C/EBP), respectively [87]. Of note, a similar downregulation of TFF1 was observed also in other murine models of gastric inflammation [88]. Furthermore, TFF1 expression is also decreased in human gastric tissue along the multi-step cascade from inflammation and NF-κB activation to adenocarcinoma [89].
However, the situation concerning TFF1 expression during H. pylori infection is probably not that simple. For example, TFF1 expression (together with IL-8 expression) is strongly induced in vitro in the gastric adenocarcinoma cell line AGS after H. pylori infection [84,90]. Here, no immune cells are present, which would secrete IL-1β. One possible explanation would be that TFF1 expression is directly activated by H. pylori via ERK signaling [85,91]. Furthermore, there are indications that TFF1 suppresses H. pylori-induced gastric inflammation in vivo and in vitro [84,92].
In sharp contrast to the down-regulation of TFF1 in gastric inflammation, TFF1 expression is ectopically induced in different organs in chronic inflammatory diseases [59,93,94] as well as in different animal models of inflammation, such as encephalitis [95], asthma [62,96], pancreatitis [94], and in the murine spleen after Toxoplasma gondii infection [97,98]. The up-regulation of TFF1 was observed also in vitro in gastric epithelial cells by the proinflammatory Th1 cytokine tumor necrosis factor (TNF)-α via NF-κB [99]. Furthermore, the up-regulation of TFF1 expression during inflammation was described to occur via the transcription factor forkhead box (FOX) FOXA1 and FOXA2 (formerly: hepatocyte nuclear factors 3 α and β), which bind in human and rodent TFF1 promoters to motif IV, close to the TATA box [100]. These winged helix domain transcription factors play a role in acute-phase response and inflammatory processes [101]. Furthermore, the Th2 cytokine IL-13 also up-regulated TFF1 in bronchial epithelial cells in vitro and in an in vivo model; of note, FOXA2 was down-regulated and FOXA3 was up-regulated in this system [102]. In a murine asthma model, IL-13 seems to induce TFF1 expression in Clara cells (Clara cell metaplasia), which are able to trans-differentiate into goblet cells [62,96].
Minute amounts of TFF1 are also synthesized in the brain, for example, in astrocytes [12]. In the latter, TFF1 expression can be induced in vitro by IL-6, IL-7, and TNFα [106]. TNF-α has been shown to up-regulate TFF1 expression via NF-κB [99]. Furthermore, TFF1 (but not TFF2 or TFF3) is up-regulated in two murine encephalitis models, probably in neurons (e.g., in internal granular layer of the cerebellum) [95]. Both models are accompanied by a strongly increased expression of TNF-α [95].
TFF1 (but not TFF2 or TFF3) is also up-regulated in the immune system, e.g., in the murine spleen after T. gondii infection (two models) [97,98]. Here, TNF-α is also up-regulated [97], which could be responsible for the induced TFF1 transcription via NF-κB [99]. Furthermore, the specific up-regulation of TFF1, but not of TFF2 and TFF3, could also be induced by the binding of FOXA1 and FOXA2 to motif IV in the TFF1 promoter [100].

Regulation of TFF2 during Inflammation
In contrast to TFF1, TFF2 was only transiently reduced in the human stomach after H. pylori infection [83]. TFF2 is rather up-regulated in inflammatory conditions as shown for various diseases [107], as well as in murine models of gastric inflammation [88] and allergic airway disease [108]. For example, gastrin-deficient mice exhibit chronic inflammation in the hypochlorhydric stomach and the Th1 cytokine interferon-gamma (IFN-γ) is the most abundant pro-inflammatory cytokine [109]. Using the gastric cell line NCI-N87, TFF2 expression was induced by IFN-γ [109]. In MKN45 gastric cells, the nuclear peroxisomeproliferator-activated receptor γ (PPARγ) regulates TFF2 expression via a non-canonical response element (PPRE) [110]; other than typical PPARγ ligands, such as troglitazone, non-steroidal anti-inflammatory drugs (NSAIDs), such as indomethacin, can induce TFF2 expression by activating PPARγ [110].
Furthermore, TFF2 was strongly induced in the lung in murine asthma models by the Th2 cytokines, IL-4 and IL-13 [111]. TFF2 induction can occur in both a STAT6-dependent manner (by IL-4, IL-13, and ovalbumin) and a STAT6-independent mechanism (by chronic expression of IL-4 or by the allergen Aspergillus fumigatus) [111]. The Th2 cytokine-mediated induction of TFF2 expression probably occurs via an indirect mechanism, as the TFF2 promoter is not known to contain a STAT-binding site but is rather regulated via GATA6 [111]. TFF2 was also induced in vivo in the murine lung as well as in vitro in human bronchial epithelial cell cultures by IL-13 [102]. Thus, TFF2 seems to be inducible during inflammation in different ways, i.e., by the Th2 cytokines IL-4 and IL-13 as well as by allergens.
Minute amounts of TFF2 are also expressed in the immune system, such as the thymus, bone marrow, spleen (memory T cells), lymph nodes, and peritoneal macrophages [14][15][16][17][18]. In the rat spleen, there is a biphasic regulation of TFF2 (up-regulation starting at 96 h) following lipopolysaccharide (LPS) administration; the latter induces an inflammatory reaction [14].

Regulation of TFF3 during Inflammation
The Th2 cytokines IL-4 and IL-13 up-regulate TFF3 expression in vitro via the transcription factor STAT6 [112]. Of special note, the heterodimer partner of TFF3, i.e., FCGBP, is also up-regulated by IL-13 [102,113]. This points to a co-ordinate expression of these disulfidelinked partner proteins during Th2 inflammation. Furthermore, in rodent models, TFF3 expression is increased in the colon after infection with pathogens, such as Nippostrongy-lus brasiliensis [114], Bifidobacterium dentium [115], and co-infection with Giardia muris and Citrobacter rodentium [116]. The latter is dependent on the NLRP3 inflammasome [116]. In contrast, infection with Citrobacter rodentium alone reduces TFF3 expression and Rag KO (T and B cell-deficient) mice did not exhibit this reduction [116,117]. Thus, it is mainly the host immune system that modulates the function of the goblet cells [117].
On the other hand, mice with a mutated gp130 signal-transducing chain (gp130 ∆STAT ) of the IL-6/IL-11 receptor had a reduced Tff3 level and impaired intestinal wound healing [91]. This phenoptype is remarkably similar to that of Tff3 KO mice [120]. Thus, in this in vivo model, TFF3 expression seems to depend on IL-6-triggered STAT1/3 signaling [81,91,103].
TFF3 is also linked to the intestinal innate immune response as its expression is induced after activation of Toll-like receptor 2 (TLR2) by commensal bacteria [121]. This is probably a secondary effect, as goblet cells probably do not express TLR2. Of special note, a severe form of ulcerative colitis (pancolitis) is associated with the heterozygous TLR2-R753Q polymorphism [122], which failed to induce TFF3 synthesis, at least in vitro [121].
Minor amounts of TFF3 are expressed in lymphatic organs such as the thymus and bone marrow as well as the spleen (memory T cells) and lymph nodes [14,15,123]. In the murine thymus, TFF3 expression is up-regulated by the autoimmune regulator (Aire) [123]. In the rat spleen, there is a biphasic regulation of TFF3 (up-regulation starting at 14 h) after exposure to LPS [14].
In the rodent and human brain, minute amounts of TFF3 are expressed mainly in neurons and also in the choroid plexus, but not in astrocytes or resting microglial cells [124][125][126][127]. Of note, in rodent primary cultures, TFF3 expression was detected in neurons as well as in activated microglial cells, but not in astrocytes [126]. The expression in activated microglial cells points to a neural immune function of TFF3, as these cells are the resident myeloid cells of the CNS, forming its innate immune defense [128].

Role of TFF Peptides for Inflammatory Processes
Generally, the role of TFF peptides in influencing inflammatory processes can be investigated by loss-of-function models (e.g., various Tff -deficient mice) and by gainof-function studies (e.g., direct application of TFF peptides). Of special note, there is a remarkably limited number of convincing reports describing significant effects of TFF peptides (e.g., in vitro) in gain-of-function studies; there are specific and sensitive readouts missing, which would allow direct functional measurements. This might be a further indication that the major functions of TFF peptides probably do not rely on simple ligation to high-affinity transmembrane receptors and triggering signaling cascades.

Loss of TFF1 Is Linked to Antral Inflammation and Cancer
Tff1 KO mice, in contrast to Tff2 KO und Tff3 KO mice, have a severe phenotype, i.e., they all develop adenomas in the gastric antral and pyloric mucosa and about 30% progress to carcinomas [105,129]. As early as 3 days postnatally, pits and glands in the antropyloric region are elongated due to severe hyperplasia and there is an expansion of proliferating epithelial progenitor cells, the latter being almost entirely devoid of mucus [129,130]. Interestingly, gp130 757F mutants with blocked SHP2-Ras-ERK signaling of the IL-6/IL-11 receptor show strongly reduced Tff1 levels and a similar phenotype [104]. In Tff1 KO mice, Tff2 expression is also drastically reduced, particularly in the gastric corpus, but not so much in the pancreas [9,129,131]. From results with gp130 757F mutants and gp130 757F /Tff2 KO mice [132], one might conclude that the reduced Tff2 level in Tff1 KO mice probably exacerbates antral tumorigenesis. The loss of TFF1 is associated with activation of NF-κBmediated chronic antral inflammation and multi-step carcinogenesis [89]. This is accompa-nied by an increased level of T lymphocytes and dramatic induction of IL-17 expression with age [133]. Of special note, the selective Cox-2 inhibitor celecoxib significantly reduced dysplastic lesions, clearly demonstrating the consecutive link of chronic inflammation and carcinogenesis [89,105,134]. Thus, Tff1 is a gastric tumor suppressor in mice [105]. In addition, the observation that TFF1 triggers a delay of the cell cycle [135] is typical of tumor suppressors. Furthermore, Tff1 KO mice show significantly higher tumor incidence after chemically-induced tumorigenesis [136].
Interestingly, at 5 months, the villi of the small intestinal mucosa were enlarged (hyperplasia) in Tff1 KO mice by a thickened lamina propria, which contained inflammatory cells [129]. A role of TFF1 outside the stomach is in line with lineage tracing studies using Tff1-Cre mice, which detected labeling also in the intestine [137]. However, Tff1 KO mice did not show an increased susceptibility to dextran sulfate sodium (DSS)-induced colitis [17].
Lineage tracing studies using transgenic Tff1-CreERT2 and Tff1-Cre mice showed that Tff1 is also expressed in long-lived stem and progenitor cells of the gastric antrum, which finally re-populate the entire antral units [137,138]. In contrast, the fundic units were only partially traced by these cells [137,138]. This is surprising and remarkable. Fundic and antral units undergo continuous self-renewal from stem and progenitor cells, but the progenitor cells differ characteristically in these units (for review, see [139]). The clonal expansion in single glands is more rapidly in the antrum when compared with the corpus [140]. Fundic units mainly contain Troy + progenitor cells at their base [141], whereas at the base of antral units, mainly Lgr5 + progenitor cells are found, which probably originate from Cckbr + progenitor cells at the +4 position [142,143]. Thus, the study with the Tff1-CreERT2 and Tff1-Cre mice would explain why inflammation and carcinogenesis in Tff1 KO mice are restricted to the antrum, as Tff1 is expressed possibly already in Lgr5 + (and maybe also in Cckbr + ) progenitor cells, but not in fundic Troy + progenitor cells [138]. This is also in line with the significant up-regulation of Cckbr and the transcription factor Mist, specifically in the gastric antrum of Tff1 KO mice [9].
Finally, the question arises on the precise molecular function of TFF1 and how a loss of TFF1 triggers gastric inflammation and carcinogenesis. Currently, at least four hypothetical models (or a combination of these) are plausible.
First, TFF1 could be an intracellular chaperone, as, in Tff1 KO mice, the unfolded protein response (UPR) is activated [41,105]. This is in agreement with the discovery of a disulfide-linked TFF1 heterodimer with a yet unknown partner protein X (TFF1-X; M r of 60k) in the human stomach; X might be a disulfide isomerase of the endoplasmic reticulum (ER) related to ERp57 [4,37]. ERp57 is not only involved in the correct folding of glycoproteins and assembly of the major histocompatibility complex (MHC class I), but also regulates gene expression via interaction with STAT3 [144]. Of note, the expression of the ER disulfide isomerase Pdia3 (i.e., the murine homologue of human ERp57) is significantly up-regulated in the gastric fundus and antrum of Tff1 KO mice [9]. This model is also in line with the observation that lectins play an important role in quality control and glycoprotein sorting in the secretory pathway [145].
Second, TFF1 was postulated to act as a scavenger for extracellular ROS/RNS due to its exposed and probably highly nucleophilic Cys VII residue [4,9,37,38]. Such protection is of particular importance for the gastric mucosa, as it is the target, as well as a potent generator, of ROS/RNS [4]. In particular, stem cells are highly sensitive to damage by ROS. An ultimate test of this hypothesis would be to check if a synthetic peptide mimicking the C-terminal Cys VII of TFF1 cures Tff1 KO mice from developing adenomas and carcinomas.
Third, TFF1 could serve as an extracellular lectin, recognizing a yet not identified glycoprotein with a terminal GlcNAcα1→R moiety or a similar structure. This unusual sugar moiety is characteristic of the mucin MUC6 from frog to human and is essential for binding the lectin TFF2 [8,36]. The addition of the terminal GlcNAcα residue is catalyzed by the enzyme α1,4-N-acetylglucosaminyltransferase (α4GnT) [146]. Remarkably, A4gnt KO mice have a very similar phenotype to Tff1 KO mice [146]. Recently, dimeric TFF1 has also been shown to bind to MUC6 as a lectin; the terminal GlcNAcα moiety or a similar structure is likely involved in this binding [37,44]. Thus, one might speculate that the ligation of TFF1, or even a modified TFF1 (e.g., sulfenylated TFF1), to MUC6 or a yet not identified transmembrane glycoprotein could serve as a signal for the correct self-renewal of antral units. Generally, TFF1 could act as an activating, as well as an inhibitory, ligand (see also Section 4.1). The latter possibility is increasingly interesting, as TFF1 has been shown to block the interaction of the IL-6 receptor IL6Rα-gp80 and gp130 (signal-transducing chain) [147], and maybe also the interaction of TNF-α and its receptor [89]. However, the known lectin interaction of MUC6 and TFF2 does not seem to play a role here, as Tff2 KO mice have a completely different phenotype to A4gnt KO mice.
Fourth, a 37k-entity of Gkn2, probably a Gkn2 homodimer, was recently detected in Tff1 KO mice, only (particularly in the antrum) [9]; the usual Tff1-Gkn2 heterodimer cannot be synthesized any more in these mice because of a lack of Tff1. Such a secretory Gkn2 homodimer may impact the inflammatory processes in the antrum or influence early differentiation. In human, the major amounts of GKN2 are hardly soluble and are probably part of the inner gastric mucus layer [37]. Tff2 KO mice did not show obvious gastrointestinal abnormalities [148]. However, in Tff2 KO mice, the degree of gastric ulceration after administration of the COX1/2 inhibitor indomethacin was significantly increased [148] and the recovery of the gastric surface from laser-induced photodamage was delayed [149]. Tff2 KO mice also exhibited accelerated progression of gastritis to dysplasia in the gastric antrum after infection with H. pylori [150] and these animals show an increased susceptibility to H. felis-induced gastritis, with enhanced gastric inflammation [16]. All these effects are in agreement with a hypothetical function of TFF2 in the gastric mucosal innate immune defense by physically stabilizing the inner mucus barrier layer due to its lectin interaction with MUC6 [4,8,20].
TFF2 expression is not limited to the gastrointestinal tract but is also present in macrophages and lymphocytes. Remarkably, peritoneal macrophages from Tff2 KO mice were hyperresponsive to IL-1β stimulation concerning the secretion of IL-6 [16]. Thus, TFF2 functions as an anti-inflammatory peptide in immune cells, negatively regulating the expression of IL-1β-induced genes. This in vitro result might be in agreement with an in vivo study, where colonic IL-6 production was dramatically reduced in a murine DSS colitis model after topical pretreatment (intracolonic route) with TFF2 [151]. A similar protective effect against DSS-induced colitis was also obtained with a TFF2-secreting Lactococcus lactis strain, which had a therapeutic effect even in chronic colitis in Il10 KO mice [152]. In contrast, Tff2 KO mice exhibited a more severe response to and a delayed recovery from DSS-induced colitis [16,17]. A conclusive explanation is not possible currently as, in Tff2 KO mice, colonic Tff3 expression is also strongly reduced, which could be the cause of this phenotype [17]. Surprisingly, the protective effect of TFF2 from DSS-induced colitis seemed to originate from colonic epithelial cells and not from colonic leucocytes, as TFF2 is not synthesized in the latter [17].
In another animal model of intestinal inflammation, Tff2 KO mice were orally infected with T. gondii [153]. In wild type mice, this leads to lethal ileitis. Surprisingly, Tff2 KO mice showed an increased baseline level of IL-12/23p40 when compared with the wild type, but they did not develop the typical intestinal immunopathology [153]. Generally, TFF2 antagonized the IL-12 release from macrophages and dendritic cells [153]. This inhibitory effect was due to cell-intrinsic TFF2 expression and could be also induced by exogenous TFF2 [153]. IL-12 is a known driver of Th1 inflammation, leading to a preferential expansion of IFN-γ-producing lymphocytes. Of note, in Tff2 KO mice, the baseline production of IFN-γ was not different, but the expansion of IFN-γ-producing Th1 cells was greatly induced after T. gondii infection [153]. Taken together, in this animal model, TFF2 is an anti-inflammatory peptide, down-regulating the expression of IL-12 in macrophages and dendritic cells, leading to a suppression of the Th1 immune response after T. gondii infection. Currently, the precise molecular mechanism of how TFF2 inhibits TLR-driven IL-12 expression is not known. A receptor blocking mechanism may be involved, as discussed in Section 4.1.
In contrast to infection with T. gondii [153], oral infection with Yersinia enterocolitica resulted in a lethal outcome in Tff2 KO mice, but not in wild type mice [154]. In Tff2 KO mice, the reduced amount of macrophages allowed Y. enterocolitica to cross the epithelial barrier of the ileum [154]. Currently, a proper explanation of these results it is not possible as there are no more molecular data available. The reduced Tff3 synthesis in Tff2 KO mice [17] may also contribute to this result.
In another set-up, nine day-old (P9) Tff2 KO rats were orally infected with E. coli, which led to bacteremia, in contrast to the wild type [155]. At this time point, intestinal Tff2 expression reaches a peak and drops sharply thereafter [156]. Thus, the increased susceptibility of Tff2 KO rats is in agreement with a function of TFF2 for the barrier integrity of the neonatal rat intestine.
In a further study, TFF2 from splenic memory T cells suppressed the expansion of splenic myeloid-derived suppressor cells (MDSC) via CXCR4 [18]. The number of MDSCs is increased in tumors where they create an inflammatory environment. Tff2 KO mice had an increased number of MDSCs and exhibited a greater number of tumors in an azoxymethane/DSS model of inflammatory colorectal carcinogenesis [18].
The inhibitory effect of TFF2 on macrophages was also demonstrated by a myeloidspecific deletion of Tff2 (Cd11c Cre Tff2 flox mice) [157]. After infection with the hookworm Nippostrongylus brasiliensis, the lung pathology was exacerbated in these mice and the proliferative expansion of epithelial alveolar type 2 cells was reduced [157]. The latter was due to the diminished expression of Wnt4 and Wnt16. Thus, myeloid-derived TFF2 also drives macrophages to accelerate epithelial regeneration after lung injury [157].
After the infection of mice with N. brasiliensis, TFF2 expression increased first in the lung (early stage) and then in the intestine (late stage); this is a prerequisite for the induction of IL-33 production, a Th2-promoting cytokine, in lung epithelial cells, alveolar macrophages, and inflammatory dendritic cells [158]. Thus, in parasitized Tff2 KO mice, the IL-33 levels are only slightly increased [158]. Of special note, the TFF2-triggered induction of IL-33 synthesis in bone marrow-derived macrophages required CXCR4 [158], which is a putative TFF2 receptor [26,27].
The TFF2-IL-33 axis has also been described in the stomach, where IL-33 is synthesized in a subpopulation of surface mucous cells, probably in precursors of surface mucous cells [159]. In the CNS and other epithelial tissues, IL-33 is expected to act as an alarmin by responding rapidly after insult [159]. In Tff2 KO mice, IL-33 expression is significantly reduced at least in the gastric fundus [159]. Furthermore, H. pylori infection also changed IL-33 expression biphasically-an acute phase with increased IL-33 followed by suppression in the chronic phase [159]. Chronic IL-33 application caused an infiltration of macrophages, neutrophils, and dendritic cells into the stomach, leading to a Th2 immune response as well as activation of the already present group 2 innate lymphoid cells (ILC2), particularly in the antrum [159]. Taken together, one could postulate that exocrine epithelial TFF2 might induce IL-33 expression in gastric surface mucus cells after injury and disruption of the gastric mucosal barrier, allowing ligation of a putative basolateral TFF2 receptor, such as CXCR4. A similar activation of a basolateral receptor after injury has been described for heregulin-α and its receptor in epithelial cells of the lung [160].
Taken together, TFF2 has a function in the normal stomach as a constituent of the gastric mucus barrier (physical stabilization of the inner, insoluble layer by strong lectin interaction with MUC6), which is a first line defense against microbial infections (innate immunity; Figure 3) [4,8,20]. In contrast, after injury or infection, TFF2 has diverse roles in the immune system and for inflammation. This explains why Tff2 KO mice have a compromised immune system [15]. On the one hand, TFF2 is a brake for myeloid cells (e.g., inhibition of IL-6 and IL-12 release) so that, in particular, Th1 inflammation after a mucosal challenge (infection) is not overshooting (anti-inflammatory effect; Figure 3) [16,18,107,153].
On the other hand, TFF2 is a positive regulator of the alarmin IL-33 in the CNS and mucous epithelia, which is an activator of a Th2 immune response after injury (Figure 3) [158,159]. interaction with MUC6), which is a first line defense against microbial infections (innate immunity; Figure 3) [4,8,20]. In contrast, after injury or infection, TFF2 has diverse roles in the immune system and for inflammation. This explains why Tff2 KO mice have a compromised immune system [15]. On the one hand, TFF2 is a brake for myeloid cells (e.g., inhibition of IL-6 and IL-12 release) so that, in particular, Th1 inflammation after a mucosal challenge (infection) is not overshooting (anti-inflammatory effect; Figure 3) [16,18,107,153]. On the other hand, TFF2 is a positive regulator of the alarmin IL-33 in the CNS and mucous epithelia, which is an activator of a Th2 immune response after injury ( Figure 3) [158,159]. Figure 3. Schematic representation of the putative functions of TFF2 in the normal gastric mucosa as well as after injury/infection. The TFF2/MUC6 complex probably stabilizes the inner gastric mucus barrier layer at the apical side of surface mucous cells (SMCs); the mucus as well as the luminal content of the stomach are separated by tight junctions from the basolateral side of SMCs. After a barrier defect, exocrine TFF2 might stimulate a putative TFF2 receptor (such as CXCR4) at the basolateral surface, leading to an increased synthesis of the nuclear alarmin IL-33 and promotion of a Th2 response (after IL-33 release probably by a non-classical secretory mechanism via exosomes [161]). Furthermore, exocrine TFF2 as well as TFF2 from endocrine sources probably have an inhibitory effect on myeloid cells (MC; see also Section 4.1), repressing a Th1 response.
Currently, it is not clear how TFF2 triggers the immune modulatory effects in the different cell types. There are multiple indications that one putative receptor is CXCR4 [18,26,27,158,162]. However, currently there are no data defining the interaction of TFF2 and CXCR4 (lectin or a protein-protein interaction). As TFF2 is a lectin, binding strongly to the O-linked GlcNAcα1→4Galβ1→R moiety of the mucin MUC6 [8,23,36,45], an interaction of TFF2 with the carbohydrate moiety of CXCR4 would be not surprising. Such a lectin interaction could also have the advantage of being specific for a cell type, depending on the glycosylation status of the cell [20]. Furthermore, signaling by TFF2 could also be more complex, e.g., by binding to glycosaminoglycans, as shown for a number of cytokines [163].

Loss of Tff3 is Linked to Increased DSS-Induced Colonic Inflammation
Tff3 KO mice develop normally and are grossly indistinguishable from their wild type littermates [120]. However, the migration of colonic crypt cells due to self-renewal of the epithelium from precursor cells was strongly delayed [120]. In the DSS-induced colitis model (2.5% DSS), Tff3 KO mice reacted much more sensitively when compared with the wild type animals [120]. Of special note, also a number of mouse strains with reduced ; the mucus as well as the luminal content of the stomach are separated by tight junctions from the basolateral side of SMCs. After a barrier defect, exocrine TFF2 might stimulate a putative TFF2 receptor (such as CXCR4) at the basolateral surface, leading to an increased synthesis of the nuclear alarmin IL-33 and promotion of a Th2 response (after IL-33 release probably by a non-classical secretory mechanism via exosomes [161]). Furthermore, exocrine TFF2 as well as TFF2 from endocrine sources probably have an inhibitory effect on myeloid cells (MC; see also Section 4.1), repressing a Th1 response.
Currently, it is not clear how TFF2 triggers the immune modulatory effects in the different cell types. There are multiple indications that one putative receptor is CXCR4 [18,26,27,158,162]. However, currently there are no data defining the interaction of TFF2 and CXCR4 (lectin or a protein-protein interaction). As TFF2 is a lectin, binding strongly to the O-linked GlcNAcα1→4Galβ1→R moiety of the mucin MUC6 [8,23,36,45], an interaction of TFF2 with the carbohydrate moiety of CXCR4 would be not surprising. Such a lectin interaction could also have the advantage of being specific for a cell type, depending on the glycosylation status of the cell [20]. Furthermore, signaling by TFF2 could also be more complex, e.g., by binding to glycosaminoglycans, as shown for a number of cytokines [163].

Loss of Tff3 Is Linked to Increased DSS-Induced Colonic Inflammation
Tff3 KO mice develop normally and are grossly indistinguishable from their wild type littermates [120]. However, the migration of colonic crypt cells due to self-renewal of the epithelium from precursor cells was strongly delayed [120]. In the DSS-induced colitis model (2.5% DSS), Tff3 KO mice reacted much more sensitively when compared with the wild type animals [120]. Of special note, also a number of mouse strains with reduced TFF3 levels showed a similar phenotype in the DSS colitis model to the Tff3 KO animals: Agr2 KO [164], Tff2 KO [17], and gp130 ∆STAT [91].
The murine colonic mucus consists of two layers: a firmly adherent inner layer, and a loose outer layer. Normally, the inner layer is devoid of bacteria [165,166]. After DSS treatment, the thickness of the inner mucus layer of the colon decreased and became permeable so that bacteria were able to penetrate and reach the epithelial cells even after 4 h [167].
This occurred before infiltration of the immune cells was observed. In wild type mice, the TFF3 expression was increased after DSS treatment in an early phase [168,169]. Thus, the increased sensitivity of Tff3 KO mice in the DSS colitis model is probably an indication that in these animals, more bacteria reach the epithelium due to an intestinal mucosal barrier defect. Most of the intestinal TFF3 forms a hetero-dimer with FCGBP, which is mucus-associated [34] and is expected to play a role in the mucosal innate immune defense by, for example, regulating pathogen attachment and the clearing of microorganisms [20]. It would be interesting to test if Tff3 KO mice show also mucosal barrier defects in the oral cavity or the urogenitary tracts, as TFF3 (and FCGBP) is also synthesized in these epithelia. Another interesting goal would also be the generation of Fcgbp KO mice and to determine their phenotype in the DSS colitis model. Furthermore, the binding of TFF3 to DMBT1 gp340 , a pattern recognition receptor with a function in mucosal innate immunity, could play a protective role here [20,25,170].
Of note, the expression of pro-inflammatory cytokines in cultured microglial cells was reduced by TFF3 [171]. This points to an anti-inflammatory function of TFF3 by the shifting of microglial cells from a M1 to a M2 phenotype, at least in vitro [171].
An immunomodulatory role of TFF3 is also in line with the observation that in the murine spleen after T. gondii infection, the expression of the inflammasome constituent Nlrp12 was significantly reduced in Tff3 KO mice when compared with wild type mice [98].

Conclusion and Medical Perspectives
Taken together, from loss-of-function studies, it is clear that Tff -deficient mice have completely different phenotypes, but all are related to inflammatory processes, either directly or after various mucosal challenges. The following picture concerning the multiple and different functions of TFF peptides has emerged (Table 1): Under physiological, healthy conditions, TFF peptides fulfill their protective functions as exocrine products mainly in the gastric mucosa (TFF1, TFF2), or in a variety of mucous epithelia (TFF3). Here, they play a role as a gastric tumor suppressor (TFF1) or they are involved in the mucosal innate immune defense as integral parts of the mucus barrier (TFF2/MUC6 lectin complex, TFF3-FCGBP heterodimer) [4,20]. As a hallmark, all three TFF peptides have lectin activities, best characterized for TFF2 [4,22]. Thus, TFF peptides as soluble lectins are comparable with multifunctional galectins and C-type lectins, which also interact with mucins [172,173]. Currently, it cannot be excluded that TFF peptides also recognize microbial glycans as certain soluble lectins do [174]. Generally, TFF peptides act at the delicate interface of epithelia, mucus/mucins, and microbia. Here, a number of medical applications are within the limits of expectation; a porcine gastric mucin preparation is already used as artificial saliva, which contains TFF2 [36]. Similar topical formulations could be used to treat patients with gastric or duodenal ulcers [20]. Equally promising are luminal applications of TFF3-FCGBP or TFF3/DMBT1gp340 for the treatment of various infections of mucous epithelia (development of anti-bacterial and anti-viral formulations) [20].
Under pathological conditions, e.g., after mucosal injury or infection, TFF2, in particular, is secreted in an endocrine fashion by myeloid cells (e.g., macrophages) and lymphocytes (e.g., memory T cells). Here, at least TFF2 is a modulator of immune reactions triggering inflammatory processes. On the one hand, TFF2 induces the synthesis and release of the nuclear alarmin IL-33, at least in mucous epithelia, which leads to a Th2 immune response. There are multiple indications that certain TFF2 effects are mediated by activating ligation to CXCR4 and/or a plethora of other glycosylated transmembrane proteins. Unfortunately, the details are not known currently. As TFF2 is a lectin recognizing, at least, the O-linked GlcNAcα1→4Galβ1→R moiety of the mucin MUC6, a lectin-triggered activation of a glycosylated transmembrane protein seems reasonable [23]. On the other hand, TFF2 inhibits myeloid cells.

Lectin-Triggered Receptor Blocking by TFF Peptides: An Hypothesis
In contrast to a proposed lectin-triggered activation of receptors [23], TFF peptides can, in particular, block the ligation of natural ligands and their cognate membrane receptors. This has been demonstrated for TFF1, which blocks the interaction of IL6Rα-gp80 (IL-6 binding chain) and gp130 (signal-transducing chain) in vitro by interaction with IL6Rα-gp80 [147]. As a consequence, several STAT3 target genes are overexpressed in Tff1 KO mice [147]. The precise nature of TFF1 binding to IL6Rα-gp80 has not been elucidated thus far, but it is tempting to speculate that TFF1 acts as a lectin binding to the carbohydrate moiety of IL6Rα-gp80, which blocks receptor activation (lectin-triggered receptor blocking hypothesis; Figure 4).
response. There are multiple indications that certain TFF2 effects ing ligation to CXCR4 and/or a plethora of other glycosylated t Unfortunately, the details are not known currently. As TFF2 i least, the O-linked GlcNAcα1→4Galβ1→R moiety of the mucin activation of a glycosylated transmembrane protein seems reaso hand, TFF2 inhibits myeloid cells.

Lectin-Triggered Receptor Blocking by TFF Peptides: An Hypothe
In contrast to a proposed lectin-triggered activation of rece can, in particular, block the ligation of natural ligands and their c tors. This has been demonstrated for TFF1, which blocks the in (IL-6 binding chain) and gp130 (signal-transducing chain) in v IL6Rα-gp80 [147]. As a consequence, several STAT3 target gen Tff1 KO mice [147]. The precise nature of TFF1 binding to IL6Rαdated thus far, but it is tempting to speculate that TFF1 acts a carbohydrate moiety of IL6Rα-gp80, which blocks receptor activ ceptor blocking hypothesis; Figure 4). Accordingly, TFF1 is a natural antagonist of the IL-6 recepto with the action of tocilizumab, a humanized anti-IL-6 receptor a the clinics for treating rheumatoid arthritis, cytokine release syn 19 [175]. A similar situation might occur in the TNF-α receptor pressed TNF-α-mediated NF-κB activation through TNFR1 [89] sion of the tissue inhibitor matrix metalloproteinase-1 (TIMP1 hyperresponsiveness of peritoneal macrophages from Tff2 KO mice might be due to the lectin binding of TFF2 to the IL-1 receptor. IL-1 receptor system by TFF2 is reminiscent of the IL-1 recep which is clinically used for treating rheumatoid arthritis. Accordingly, TFF1 is a natural antagonist of the IL-6 receptor system and comparable with the action of tocilizumab, a humanized anti-IL-6 receptor antibody, which is used in the clinics for treating rheumatoid arthritis, cytokine release syndrome and even COVID-19 [175]. A similar situation might occur in the TNF-α receptor system, where TFF1 suppressed TNF-α-mediated NF-κB activation through TNFR1 [89] and inhibited the expression of the tissue inhibitor matrix metalloproteinase-1 (TIMP1) [176]. Furthermore, the hyperresponsiveness of peritoneal macrophages from Tff2 KO mice to IL-1β stimulation [16] might be due to the lectin binding of TFF2 to the IL-1 receptor. Such an inhibition of the IL-1 receptor system by TFF2 is reminiscent of the IL-1 receptor antagonist anakinra, which is clinically used for treating rheumatoid arthritis.

New Medical Perspectives
In the future, TFF peptides might be used to specifically block a series of glycosylated receptors playing mayor roles in inflammatory processes. As glycosylation patterns are relatively cell-specific, the use of TFF peptides could be selective for specific cells. Furthermore, TFF peptides recognize different carbohydrate moieties. This combination might allow interesting future clinical applications for TFF peptides and might open new therapeutic strategies, e.g., as anti-inflammatory agents. Thus, it is now a promising goal to test systematically receptors for their binding of TFF peptides, e.g., in vitro. When using different cell lines, the knowledge of the specific glycosylation pattern is of particular interest. The use of different cell lines might explain contrary past results. As a prerequisite for such studies, the carbohydrate specificities of TFF peptides have to be elucidated in detail. Thus far, it is clear that the lectin characteristics of the three TFF peptides are different, but partly related. GlcNAc seems to be a common moiety recognized at least by TFF1 and TFF2 [4]. Furthermore, a series of mutant TFF peptides with precisely altered carbohydrate specificities could be created, which would even expand their medical potential [4,20].
As lectins with multiple connections to the immune system, TFF peptides have to be considered as promising new players in the field of glycoimmunology, such as galectins, siglecs, and C-type lectins [177,178]. In particular, galectins are able to form multivalent complexes with cell surface glycoconjugates, and such 2D and 3D cross-linked lattices could influence signal transduction [179,180]. As a prerequisite for such studies, it has to be cleared which of the polarized macrophage phenotypes and which lymphocytes synthesize which TFF peptide. In addition, it is also important to understand the rather complex regulation of TFF gene expression in these cells. For example, PPARγ is involved in the regulation of macrophage polarization [181] as well as TFF2 expression [80,110]. Furthermore, there are auto-induction mechanisms known for TFF genes [80,182] as well as epigenetic regulation via promoter methylation [11,66,80,132,[183][184][185]. Such mechanisms would be well suited for generating positive and negative feedback loops. This information is necessary not only to fully understand the numerous results particularly obtained with the Tff2 KO mice (see Section 3.2), but also for a rationale clinical application of TFF peptides.
First clinical studies already started with TFF1 and TFF3 only (probably for patent reasons) to reduce oral mucositis, which is a side effect of radio-and chemotherapy [186]. For the future, more sophisticated strategies can be expected, which could allow numerous novel medical applications for TFF peptides; possible fields would be inflammationinduced fibrosis, rheumatoid arthritis, or neurodegeneration. For example, TFF2 regulates airway remodeling [187], reversed airway fibrosis [108], and is upregulated in the synovial fluid of rheumatoid arthritis samples [188], whereas TFF3 is associated with neurodegeneration [189]. However, there are many open questions currently and there is a strong necessity for further research before application in clinics can be considered, e.g., for the treatment of various immune mediated inflammatory disorders.
Funding: This research received no external funding.
Acknowledgments: I thank Daniela Lorenz (Otto-von-Guericke University, Magdeburg) for her secretarial help, Prof. T.C. Wang (Columbia University, New York) for inspiring discussions, and Dr. Jonathan A. Lindquist (Otto-von-Guericke University, Magdeburg) for his valuable comments on the manuscript.

Conflicts of Interest:
The author declares no conflict of interest.